CTT1057

February 26, 2018February 26, 2018

New Diagnostic Tool for Metastatic Prostate Cancer Advances Following License Agreement

News

The development of CTT1057, a new product for the diagnosis of metastatic prostate cancer, received a boost with the worldwide license agreement between Novartis-held company Advanced Accelerator Applications (AAA) and ... Read more

April 18, 2017

CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences

News

The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business ... Read more

December 14, 2016December 14, 2016

Phase 1 Trial Assessing PET Imaging Agent in Local and Advanced Prostate Cancers Enrolling Patients

News

Cancer Targeted Technology (CTT) has initiated a Phase 1 clinical trial evaluating the safety and sensitivity of its positron emission tomography (PET) imaging agent, CTT1057, in detecting prostate cancer cells ... Read more